Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

frankinsense69 Aug. 24 at 6:21 PM

$CVM $NWBO Immx Sushi won He always wins Cheers

0 · Reply

frankinsense69 Aug. 24 at 6:17 PM

$CVM @NavyPatrol657 Daddy won What’s your cost IMMX says what ? Woof!

0 · Reply

frankinsense69 Aug. 24 at 5:34 PM

$CVM I was right.

0 · Reply

frankinsense69 Aug. 24 at 4:50 PM

$CVM @Isitreallyhim Like this too

0 · Reply

USAEquityResearch Aug. 24 at 4:42 PM

$CVM 📊 USAEquityResearch ▼ 1.39 (-2.11%) Trend: Cautiously bearish ↘️ RSI (14): 51.4 — neutral territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 1.72 | Support: 1.14 20-MA: 1.44 | 50-MA: 1.26 💼 Fundamentals Mkt Cap: $24.45M FCF: $-8.91M (-0.51/sh) Total Debt: $7.90M D/E: 72.1 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/CVM

0 · Reply

frankinsense69 Aug. 24 at 3:52 PM

@Isitreallyhim $CVM How exciting you mean a huge large fund is spending $15,000 a day that’s crazy. It must be something big is happening. Now tell me about immx

0 · Reply

Isitreallyhim Aug. 24 at 3:20 PM

Mr. shaved legs now talking weird a-- stuff. This guy is deeply disturbed. frankinsense69 $CVM Please buy more Kevin I want your Maga ass to get destroyed

1 · Reply

frankinsense69 Aug. 24 at 1:46 PM

$CVM Monday is usually when the SFDA makes his announcements. They are many time zones ahead of us Clearly it was decided that this was denied. I bet you would get an 8K after hours in the next couple days informing us that they have denied our request for BMD. Woof!

0 · Reply

frankinsense69 Aug. 24 at 1:11 PM

$CVM Clearly this moron Kevin has been asleep for the past four years Please buy more Kevin I want your Maga ass to get destroyed

0 · Reply

Isitreallyhim Aug. 24 at 12:30 PM

$CVM Monday morning ..... Geert you awake ???

1 · Reply

CEL-SCI reports Q3 EPS (47c) vs ($1.36) last year

Aug 17, 2026, 8:30 AM EDT - 7 days ago

CEL-SCI Reports Fiscal Third Quarter 2026 Results

2026-08-04T12:18:16.000Z - 20 days ago

CEL-SCI announces publication of study supporting multikine biomarker strategy

Aug 4, 2026, 8:00 AM EDT - 20 days ago

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

2026-07-30T12:44:01.000Z - 25 days ago

CEL-SCI announces manuscript on Phase 3 study to be published in Oral Oncology

Jul 30, 2026, 8:31 AM EDT - 25 days ago

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

2026-07-13T12:10:18.000Z - 6 weeks ago

CEL-SCI to launch FDA registration-enabling Phase 3 Confirmatory study

Jul 13, 2026, 8:00 AM EDT - 6 weeks ago

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

2026-06-24T12:11:05.000Z - 2 months ago

CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

Jun 16, 2026, 4:01 PM EDT - 2 months ago

CEL-SCI Announces Closing of Offering

2026-06-16T12:14:11.000Z - 2 months ago

CEL-SCI highlights dual-track strategy for Multikine

Jun 16, 2026, 8:00 AM EDT - 2 months ago

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

Jun 14, 2026, 7:03 PM EDT - 2 months ago

CEL-SCI Corporation Announces Pricing of Offering

2026-06-12T12:11:21.000Z - 2 months ago

CEL-SCI, Saudi Amarox to conduct signing ceremony for strategic agreement

Jun 12, 2026, 8:00 AM EDT - 2 months ago

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

2026-05-18T12:10:09.000Z - 3 months ago

CEL-SCI reports Q2 EPS (67c) vs. ($2.33) last year

May 18, 2026, 8:00 AM EDT - 3 months ago

CEL-SCI Reports Fiscal Second Quarter 2026 Results

May 13, 2026, 3:00 PM EDT - 3 months ago

CEL-SCI Announces Closing of Public Offering

2026-05-12T02:55:09.000Z - 3 months ago

CEL-SCI 6M share Secondary priced at $1.20

May 11, 2026, 8:11 PM EDT - 3 months ago

CEL-SCI Corporation Announces Pricing of Public Offering

2026-05-11T16:53:15.000Z - 3 months ago

CEL-SCI enters strategic agreement with Amarox over Multikine distribution

May 11, 2026, 8:00 AM EDT - 3 months ago

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

2026-04-17T21:13:20.000Z - 4 months ago

CEL-SCI files to sell 3.44M shares of common stock

Feb 18, 2026, 9:00 AM EST - 6 months ago

CEL-SCI Reports Fiscal First Quarter 2026 Results

Dec 29, 2025, 9:00 AM EST - 8 months ago

CEL-SCI Reports Fiscal 2025 Results

2025-11-07T21:35:28.000Z - 10 months ago

CEL-SCI files to sell 375,000 shares of common stock for holders

Oct 20, 2025, 9:00 AM EDT - 11 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 10, 2025, 8:00 AM EDT - 11 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Aug 29, 2025, 12:52 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10 Million Public Offering

2025-08-28T03:45:10.000Z - 1 year ago

CEL-SCI 1.11M share Spot Secondary priced at $9.00

Aug 27, 2025, 10:35 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $10 Million Public Offering

2025-08-27T21:30:16.000Z - 1 year ago

CEL-SCI announces common stock offering, no amount given

Aug 27, 2025, 5:25 PM EDT - 1 year ago

CEL-SCI Announces Proposed Public Offering

2025-08-14T14:50:29.000Z - 1 year ago

CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year

Aug 14, 2025, 10:45 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

2025-08-13T13:25:31.000Z - 1 year ago

CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia

Aug 13, 2025, 9:15 AM EDT - 1 year ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 9:15 AM EDT - 1 year ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 1 year ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 21, 2025, 8:14 PM EDT - 1 year ago

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025, 2:40 PM EDT - 1 year ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 1 year ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 8, 2025, 9:51 AM EDT - 1 year ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Mar 24, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 2 years ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 2 years ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 2 years ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 2 years ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

frankinsense69 Aug. 24 at 6:21 PM

$CVM $NWBO Immx Sushi won He always wins Cheers

0 · Reply

frankinsense69 Aug. 24 at 6:17 PM

$CVM @NavyPatrol657 Daddy won What’s your cost IMMX says what ? Woof!

0 · Reply

frankinsense69 Aug. 24 at 5:34 PM

$CVM I was right.

0 · Reply

frankinsense69 Aug. 24 at 4:50 PM

$CVM @Isitreallyhim Like this too

0 · Reply

USAEquityResearch Aug. 24 at 4:42 PM

0 · Reply

frankinsense69 Aug. 24 at 3:52 PM

@Isitreallyhim $CVM How exciting you mean a huge large fund is spending $15,000 a day that’s crazy. It must be something big is happening. Now tell me about immx

0 · Reply

Isitreallyhim Aug. 24 at 3:20 PM

Mr. shaved legs now talking weird a-- stuff. This guy is deeply disturbed. frankinsense69 $CVM Please buy more Kevin I want your Maga ass to get destroyed

1 · Reply

frankinsense69 Aug. 24 at 1:46 PM

0 · Reply

frankinsense69 Aug. 24 at 1:11 PM

$CVM Clearly this moron Kevin has been asleep for the past four years Please buy more Kevin I want your Maga ass to get destroyed

0 · Reply

Isitreallyhim Aug. 24 at 12:30 PM

$CVM Monday morning ..... Geert you awake ???

1 · Reply

Johnyd Aug. 24 at 3:09 AM

$CVM "..................GEERT is incompetent -" not too late to get rid of him. even this stock would 2x

0 · Reply

frankinsense69 Aug. 22 at 4:27 PM

$IMMX trending $CVM $NWBO

0 · Reply

prophet777 Aug. 22 at 6:27 AM

$CVM this thing never disappoints… always down :)

0 · Reply

Johnyd Aug. 21 at 10:46 PM

$CVM 1 month till the "end of the summer"

0 · Reply

Johnyd Aug. 21 at 10:30 PM

$CVM PUFFY:no active BMA. No patient trial enrolled TRIAL MUST BE IN USA !

0 · Reply

USAEquityResearch Aug. 21 at 9:42 PM

$CVM 📊 USAEquityResearch ▼ 1.42 (-2.74%) Trend: Cautiously bearish ↘️ RSI (14): 57.4 — neutral territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 1.72 | Support: 1.14 20-MA: 1.43 | 50-MA: 1.26 💼 Fundamentals Mkt Cap: $24.98M FCF: $-8.49M (-0.48/sh) Total Debt: $7.90M D/E: 72.1 Educational content only. Not financial advice.

0 · Reply

Isitreallyhim Aug. 21 at 6:16 PM

$CVM Saudi closed. Monday could be the day. Buy the dip from yesterday

1 · Reply

frankinsense69 Aug. 21 at 4:05 PM

$CVM immx new all time hi Hi morons Daddy won

0 · Reply

frankinsense69 Aug. 21 at 2:41 PM

$CVM how are the losers here? Immx says what Hi navy Hi cvmsuperdong

1 · Reply

chaerophon Aug. 21 at 1:06 AM

$CVM much effort has been spent to pin otm to the 1.50 strike price for option expiration tomorrow as implied volatility galactically casts mountainous latin shadows from a calendar many suspect may have started on Sunday May 31st, 2026.

2 · Reply

frankinsense69 Aug. 20 at 7:47 PM

$CVM An urgent message everybody look out 🤣🤣

1 · Reply

frankinsense69 Aug. 20 at 6:47 PM

$CVM it was denied AK after hours this thing will be $.30 on Friday morning

0 · Reply

Market Cap	24.82M
Revenue (ttm)	0.00
Net Income (ttm)	-25.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	99,505
Avg Vol	351,084
Day's Range	N/A - N/A
Shares Out	17.48M
Stochastic %K	0%
Beta	0.63
Analysts	Strong Sell
Price Target	$180.18